PHILADELPHIA — (Feb. 4, 2022) — Nearly four decades after its discovery, HIV has killed 36.3 million people, with no vaccine in sight. However, a new study by researchers at The Wistar Institute, a…
PHILADELPHIA — (Feb. 1, 2022) — The first generation of COVID-19 vaccines have been highly effective, but also have limitations: their efficacy can wane without a booster shot, and they may be less…
Wistar is a finalist of the STEM Talent Challenge to create a new life science workforce training program to address Pennsylvania industry growth and demand for skilled workers. U.S. Assistant Secr…
PHILADELPHIA — (Jan. 17, 2022) — A new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, …
PHILADELPHIA — (Jan. 5, 2022) — The Wistar Institute announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carci…
PHILADELPHIA — (Dec. 2, 2021) — Fox Chase Cancer Center has opened an investigator-initiated, phase 1 clinical trial to evaluate the safety and efficacy of gamitrinib in patients with advanced canc…
PHILADELPHIA — (Nov. 30, 2021) — Immunotherapies have shown striking clinical benefit in the treatment of many cancers, especially when used in combination with chemotherapy. However, some cancers …
PHILADELPHIA — (Nov. 23, 2021) — The Commonwealth of Pennsylvania has granted The Wistar Institute $4 million to fund COVID-19 research focused on understanding the impact of COVID-19 on certain at…
PHILADELPHIA — (Nov. 11, 2021) — A new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, …
PHILADELPHIA—(October 14, 2021)—The Wistar Institute is proud to announce Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, National Institutes of Healt…
